Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
159.60
+0.41 (0.26%)
Mar 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 158.86 - 161.48
52 week 108.20 - 173.14
Open 160.00
Vol / Avg. 2.47M/3.53M
Mkt cap 121.02B
P/E 23.82
Div/yield 0.79/1.98
EPS 6.70
Shares 758.86M
Beta 0.57
Inst. own 82%
Apr 20, 2015
Q1 2015 Amgen Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 16, 2015
Amgen Inc Conference Call to Discuss Cardiovascular Development Program at American College of Cardiology Scientific Session & Expo - 4:00PM EDT - Add to calendar
Mar 2, 2015
Amgen Inc at Cowen Health Care Conference - Webcast
Jan 27, 2015
Q4 2014 Amgen Inc Earnings Call - Webcast
Jan 27, 2015
Q4 2014 Amgen Inc Earnings Release
Jan 13, 2015
Amgen Inc at JPMorgan Healthcare Conference - Q&A Session
Jan 13, 2015
Amgen Inc at JPMorgan Healthcare Conference
Jan 5, 2015
Amgen and Kite Pharma Inc Strategic Cancer Immunotherapy Collaboration
Dec 8, 2014
Amgen Inc Investor Meeting at American Society of Hematology Annual Meeting - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 24.27% 25.71%
Operating margin 27.37% 30.86%
EBITD margin - 43.16%
Return on average assets 7.43% 7.63%
Return on average equity 20.31% 21.55%
Employees 17,900 -
CDP Score - 64 C

Address

1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It focuses its research and development activities on human therapeutics for in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company�s marketed products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, Sensipar/Mimpara, XGEVA and Prolia. In addition to its marketed products, the Company has various product candidates in mid-to late-stage of development. The Company markets its principal products primarily in the United States in cancer care, inflammation, nephrology and bone disease. As of February 17, 2014, the Company has 16 Phase III programs.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
David W. Meline Chief Financial Officer, Executive Vice President
Age: 56
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 63
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 51
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 59
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 57
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 52
Bio & Compensation  - Reuters
David J. Scott Senior Vice President, General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Stuart A. Tross Senior Vice President - Human Resources
Age: 47
Bio & Compensation  - Reuters
Steven K. Galson M.D. Senior Vice President - Global Regulatory Affairs And Safety
Age: 57
Bio & Compensation  - Reuters